CUTANEOUS SQUAMOUS CELL CARCINOMA
Clinical trials for CUTANEOUS SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for CUTANEOUS SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Cancer combo trial halted early: no breakthrough yet
Disease control TerminatedThis study tested a new drug (SOT101) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, and it is not a cure—patients still need ongoing tre…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: SOTIO Biotech AG • Aim: Disease control
Last updated May 26, 2026 08:41 UTC
-
New drug tested for hard-to-treat cancers
Disease control TerminatedThis study tested an experimental drug called INCB099318 in 105 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 26, 2026 08:40 UTC
-
Promising combo for advanced cancers hits snag: trial terminated early
Disease control TerminatedThis study tested whether combining two drugs—vidutolimod (injected into tumors) and cemiplimab (given through a vein)—could shrink or control advanced cancers like Merkel cell carcinoma, skin cancer, breast cancer, lung cancer, and throat cancer. The trial enrolled 77 adults and…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Promising skin cancer combo study halted early
Disease control TerminatedThis study tested whether adding an experimental drug (NT-I7) to an existing immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial enrolled 31 adults whose cancers had not responded t…
Matched conditions: CUTANEOUS SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated May 18, 2026 12:07 UTC